WO2001022945A1 - Vasopressin antagonist formulation and process - Google Patents

Vasopressin antagonist formulation and process Download PDF

Info

Publication number
WO2001022945A1
WO2001022945A1 PCT/US2000/026369 US0026369W WO0122945A1 WO 2001022945 A1 WO2001022945 A1 WO 2001022945A1 US 0026369 W US0026369 W US 0026369W WO 0122945 A1 WO0122945 A1 WO 0122945A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
pharmaceutical composition
polysorbate
weight
polyethylene glycols
Prior art date
Application number
PCT/US2000/026369
Other languages
French (fr)
Inventor
Joseph Kyuwung Yoon
Richard William Saunders
Mahdi Bakir Fawzi
Original Assignee
American Cyanamid Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA02003189A priority Critical patent/MXPA02003189A/en
Priority to EA200200414A priority patent/EA200200414A1/en
Priority to EP00965430A priority patent/EP1216033A1/en
Priority to PL00354282A priority patent/PL354282A1/en
Priority to HU0202972A priority patent/HUP0202972A3/en
Priority to IL14854100A priority patent/IL148541A0/en
Priority to AU76150/00A priority patent/AU7615000A/en
Priority to JP2001526157A priority patent/JP2003510269A/en
Application filed by American Cyanamid Company filed Critical American Cyanamid Company
Priority to BR0014351-0A priority patent/BR0014351A/en
Priority to KR1020027003931A priority patent/KR20020039354A/en
Priority to CA002388474A priority patent/CA2388474A1/en
Publication of WO2001022945A1 publication Critical patent/WO2001022945A1/en
Priority to NO20021475A priority patent/NO20021475L/en
Priority to HK02106544.6A priority patent/HK1045109A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Definitions

  • U.S. Patent No. 4,620,974 (Hersh et al.) teaches a hard gelatin capsule comprising a telescoping two-piece cap with a lubricant comprising a polyethylene glycol of a molecular weight between about 200 and about 900 present in admixture with the composition at a concentration of from about 0.5 to about 25 weight percent.
  • WO 96/40071 discloses methods and devices for producing minimal volume capsules.
  • WO 96/41622 teaches suspensions suitable for encapsulation in gelatin capsules, particularly including a solid phase of solid particles and a liquid phase capable of suspending the solid phase.
  • U.S. Patent No. 5,641,512 (Cimiluca) teaches soft gelatin encapsulated analgesics in which the shell contains a xanthine derivative, such as caffeine.
  • U.S. Patent No. 4,578,391 (Kawata et al.) describes oily compositions for antitumor agents comprising at least one sparingly oil soluble or water-soluble antitumor drug, at least one fat or oil, and at least one solubilizing adjuvant in an oily vehicle, selected from crown ether, lecithin, polyethylene glycol, propylene glycol, vitamin E, polyoxyehtylene alkylether, and sucrose esters of fatty acids.
  • EP 0 815 854 Al discloses a substantially translucent, semi-solid fill material for a soft gelatin capsule, the semi-solid material being sufficiently viscous that it cannot be expelled from the capsule with a syringe at room temperature.
  • U.S. Patent No. 4,744,988 (Brox) teaches soft gelatin capsules comprising a shell of gelatin, a softener and a filling of a polyethylene glycol and a low polyhydric alcohol and at least one active substance, characterized in that the shell contains 4 to 40 percent sorbital or sorbitanes, at least half of the weight of polyethylene glycol used is a polyethylene glycol having a mean molecular weight of 600, and the capsule filling comprises up to 20% by weight of glycerol and or 1,2-propylene glycol.
  • WO 95/19579 (Dhabhar) teaches a process for solubilizing difficulty soluble pharmaceutical agents in a mixture of polyethylene glycol and propylene glycol by using a polyvinylpyrrolidone with a specific viscosity average molecular weight of from about 5,000 to about 25,000.
  • This invention provides orally administerable formulations for N-[4-(5H- pyrrolo[2,l-c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, also known as VPA-985, or the pharmaceutically acceptable salts thereof, which has the structure:
  • VPA-985 is a V2 receptor antagonist (vasopressin antagonist) with the ability to elicit the removal of water in mammals, without the excretion of necessary electrolytes.
  • V2 receptor antagonist vasopressin antagonist
  • NPA-985 can be seen as Example 482 in U.S. Patent No. 5,516,774.
  • This compound is highly insoluble in both conventional, orally acceptable oils, such as safflower or sesame seed oils, and in aqueous systems. Therefore, its pharmaceutical formulation requires a novel approach.
  • compositions of this invention comprise (by % w/w):
  • PEG polyethylene glycols
  • PVP polyvinylpyrrolidone
  • Suitable pharmaceutically acceptable salts of N-[4-(5H-pyrrolo[2,l- c] [ 1 ,4]benzodiazepin- 10( 1 lH)ylcarbonyl)-3-chlorophenyl] -5-fluoro-2- methylbenzamide include those derived from organic and inorganic acids such as lactic, citric, acetic, tartaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic and similarly known acceptable acids.
  • the polyethylene glycol component may be comprised of one or more PEG polymers, preferably commercially available PEG polymers between PEG 200 and
  • PEG 4,000 i.e. those PEG polymers having an average molecular weight between about 190 and about 4800. More preferred are PEG polymers between average molecular weights of from about 190 to about 3450, most preferably between about 400 and 1540. Among the preferred PEG polymers are PEG 400, having an average molecular weight between about 380 and about 420, and PEG 1,000, having an average molecular weight between about 950 and about 1050. The ratio of high and low molecular weight PEG species within the PEG component is preferably from about 2.5:1 to about 1:2.5, more preferably about 1:1. As an example, a preferred blend of PEG polymers within this invention would include a 1 : 1 blend of PEG 400 and PEG 1000.
  • Mixtures of final components which have a viscosity range of from about 140 to about 1500 centipoise at 37°C may be preferred, more preferably a range of from 300 to about 800 centipoise at 37°C.
  • the surfactants that may be used with the present formulations include, but not limited to, polysorbate 20 (polyoxyethylene 20 sorbitan monolaurate), Polysorbate 60, Polysorbate 40, polysorbate 80, Span 80 Sorbitan Oleate, a product of ICI Americas, Wilmington, Delaware, polysorbate 81, polysorbate 85, polysorbate 120, bile acids and their salts defined by Martindale The Extra Pharmacopoeia Thirtieth Edition on pagel341-1342 such as Sodium taurocholates, Sodium deoxytaurocholates, Chenodeoxycholic acid, and ursodeoxycholic acid, and pluronic or poloxamers such as Pluronic F68, Pluronic L44, Pluronic LlOl, or combinations of one or more of the above. Polysorbate 80, by itself or in combination with one or more other surfactants, is preferred for use with this invention.
  • sucrose fatty acid esters useful with this invention include those commercially available and art recognized esters useful for orally administered pharmaceutical compositions, including monoesters, diesters and triesters of sucrose, or mixtures or blends thereof.
  • Specific examples of esters useful with this invention are sucrose monolaurate, sucrose monomyristate, sucrose monopalminate, sucrose monostearate, sucrose distearate, sucrose tristearate, sucrose trimyristate, and sucrose tripalmitate, or combinations thereof.
  • other enhancing or protective pharmaceutically acceptable antioxidants or preservatives may be added to the compositions of this invention to comprise up to about 4% of the composition, by weight, more preferably up to about 3%.
  • Examples may include ascorbyl palmitate, benzyl alcohol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • examples of these components in the present formulations would include BHA at a concentration from about 0.3% to about 2.5% (% w/w) and BHT at a concentration from about 0.005% to about 0.15% (% w/w), preferably with a mixture of BHA and BHT within these ranges. Further embodiments include about 0.2% BHT.
  • a formulation of this invention utilizing one or more of these antioxidants or preservatives comprises:
  • PVP polyvinylpyrrolidone
  • the formulations of this invention are enclosed in a sealed enclosure after manufacture, such as soft or hard gelatin capsules.
  • the formulations of this invention may be created as a liquid or semi-liquid formulation and introduced into a capsule. Similarly, using an acceptable range of components and/or temperatures, the formulation may be made as a gel or solid prior to encapsulation.
  • This invention also includes a method for producing the formulations disclosed herein.
  • the process comprises the steps of:
  • sucrose fatty acid ester(s) and or povidone preferably with stirring until the final pharmaceutical composition mixture is clear.
  • optional antioxidants or preservatives such as BHA
  • the PEG component such as a mixture of PEG 400 and PEG 1000
  • the surfactant component such as Polysorbate 80
  • a fluid or semi-solid composition may be produced with the more fluid PEG, surfactant and PVP species within the scope of this invention. More gel-like, viscous or semi-solid compositions may be produced with combinations of higher molecular weight PEG components and PVP components having higher K values. Moreover, the components may be cooled below their melting point if milling or other processing of the final composition is desired.
  • a fluid composition of this invention may be sprayed onto a cooled Teflon®-coated surface to form small solid spheres, which may be individually coated or collected for further processing.
  • polysorbate 80 in this formulation of Example 1, other polysorbate series such as Tween 20, 40 and 60 can also be used, alone or in combination with each other and/or polysorbate 80.
  • step 4. Cool the solution in step 4. to 60 ⁇ 5 °C. 5. Add Povidone, USP, K-17 (Plasdone C-15, ISP) slowly to step 5, to prevent the formation of lumps.
  • Example 3 50 mg/capsule
  • Example 3 provides a formulation with a combination of two or more surfactants.
  • Example 3 The formulation of Example 3 is manufactured the same as that of Example 1 (50 mg/capsule) with the exception that two surfactants, polysorbate 40 and poloxamer 188 were added in step 1 along with PEG 400 and PEG 1000.
  • the encapsulation weight is 480 mg.
  • Example 4 The formulation of Example 4 is produced in the same manner as that of 50 mg/capsule, above, with the exception that the heating temperature to solubilize VPA- 985 in step 3 is 115 ⁇ 5 °C, instead of 120 ⁇ 5 °C.
  • the encapsulation weight is 455 mg.
  • This formulation is produced with the same steps as the 50 mg/capsule, above, with the exception that the heating temperature to solubilize VPA-985 in step 3 is 145 ⁇ 5 °C, instead of 120 ⁇ 5 °C.
  • the encapsulation weight is 650 mg in size 0 hard gelatin capsule.
  • VPA-985 150 mg in Size 00 Capsule
  • Inactive Ingredients PEG 1000, NF 26.3 239.33 4,786.60 Povidone USP K-17 15 136.50 2,730.00
  • Example 6 This formulation of Example 6 is produced with the same steps as that of 50 mg/capsule with the exception of the heating temperature to solubilize VPA-985 in step 3 is 150 ⁇ 5 °C, instead of 145 ⁇ 5 °C.
  • the encapsulation weight is 910 mg in size 00 hard gelatin capsule.
  • Examples 12 through 32 were formulated by the methods herein using PEG 400, PEG 1000, PVP with a K value of 17, VPA-985, BHA and BHT as antioxidants or preservatives and the additional components listed as "other".
  • Active Ingredient VPA-985 @100% 10.42 25 500.00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides novel formulations for N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methyl-benzamide, or a pharmaceutically acceptable salt thereof, and processes for making them, the formulations comprising from about 1 % to about 20 % of active ingredient, from about 1 % to about 18 % of a surfactant component, from about 50 % to about 80 % of a component of one or more polyethylene glycols, from about 1 % to about 20 % of a component of one or more sucrose fatty acid esters and/or polyvinylpyrrolidone and, optionnaly, one or more pharmaceutically acceptable preservatives or antioxidants.

Description

VASOPRESSIN ANTAGONIST FORMULATION AND PROCESS
This applications concerns new formulations for N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(l lH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, and pharmaceutically acceptable salts thereof, as well as processes for manufacturing the formulations. The invention particularly relates to orally administered formulations of these compounds.
Background of the Invention
The art describes many methods of producing liquid or semi-solid encapsulated pharmaceutical formulations. In Bull. Tech./Gattefosse Rep. (1996), 89, 27-38, authors Shah et al. describe hard gelatin capsule technology, particularly for use in enhancing the bioavailability of poorly soluble or poorly absorbed drugs.
U.S. Patent No. 4,620,974 (Hersh et al.) teaches a hard gelatin capsule comprising a telescoping two-piece cap with a lubricant comprising a polyethylene glycol of a molecular weight between about 200 and about 900 present in admixture with the composition at a concentration of from about 0.5 to about 25 weight percent.
WO 96/40071 (Lamberti) discloses methods and devices for producing minimal volume capsules. WO 96/41622 (Tanner et al.) teaches suspensions suitable for encapsulation in gelatin capsules, particularly including a solid phase of solid particles and a liquid phase capable of suspending the solid phase.
U.S. Patent No. 5,641,512 (Cimiluca) teaches soft gelatin encapsulated analgesics in which the shell contains a xanthine derivative, such as caffeine. U.S. Patent No. 4,578,391 (Kawata et al.) describes oily compositions for antitumor agents comprising at least one sparingly oil soluble or water-soluble antitumor drug, at least one fat or oil, and at least one solubilizing adjuvant in an oily vehicle, selected from crown ether, lecithin, polyethylene glycol, propylene glycol, vitamin E, polyoxyehtylene alkylether, and sucrose esters of fatty acids.
EP 0 815 854 Al discloses a substantially translucent, semi-solid fill material for a soft gelatin capsule, the semi-solid material being sufficiently viscous that it cannot be expelled from the capsule with a syringe at room temperature.
U.S. Patent No. 4,744,988 (Brox) teaches soft gelatin capsules comprising a shell of gelatin, a softener and a filling of a polyethylene glycol and a low polyhydric alcohol and at least one active substance, characterized in that the shell contains 4 to 40 percent sorbital or sorbitanes, at least half of the weight of polyethylene glycol used is a polyethylene glycol having a mean molecular weight of 600, and the capsule filling comprises up to 20% by weight of glycerol and or 1,2-propylene glycol.
WO 95/19579 (Dhabhar) teaches a process for solubilizing difficulty soluble pharmaceutical agents in a mixture of polyethylene glycol and propylene glycol by using a polyvinylpyrrolidone with a specific viscosity average molecular weight of from about 5,000 to about 25,000.
Summary of the Invention
This invention provides orally administerable formulations for N-[4-(5H- pyrrolo[2,l-c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, also known as VPA-985, or the pharmaceutically acceptable salts thereof, which has the structure:
Figure imgf000004_0001
VPA-985 is a V2 receptor antagonist (vasopressin antagonist) with the ability to elicit the removal of water in mammals, without the excretion of necessary electrolytes. The synthesis of this compound and its salts is disclosed in U.S. Patent No. 5,516,774 (Albright et al.), which is fully incorporated herein by reference. NPA-985 can be seen as Example 482 in U.S. Patent No. 5,516,774. This compound is highly insoluble in both conventional, orally acceptable oils, such as safflower or sesame seed oils, and in aqueous systems. Therefore, its pharmaceutical formulation requires a novel approach.
The formulations of this invention comprise (by % w/w):
a) from about 1% to about 20% of N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof, preferably from about 1% to about 16% or from about 5% to about 16% or from about 5% to about 18% of this active ingredient;
b) from about 1% to about 18% of a surfactant component, preferably from about 5% to about 18% or from about 5% to about 15% of the surfactant component, more preferably from about 5% to about 10% of the surfactant component;
c) from about 50% to about 80% of a component of one or more polyethylene glycols (PEG), preferably from about 55% to about 70% of one or more different molecular weight grades of polyethylene glycols; and
d) from about 1% to about 20%, preferably from about 5% to about 15% and more preferably between about 8% and about 12%, of a component of: i) one or more sucrose fatty acid esters; or ii) a polyvinylpyrrolidone (PVP) with a K value between about 15 and 90, preferably with a K value of from about 17 as defined in USP/NF; or iii) a combination of one or more sucrose fatty acid esters and a PVP, as defined above.
Suitable pharmaceutically acceptable salts of N-[4-(5H-pyrrolo[2,l- c] [ 1 ,4]benzodiazepin- 10( 1 lH)ylcarbonyl)-3-chlorophenyl] -5-fluoro-2- methylbenzamide include those derived from organic and inorganic acids such as lactic, citric, acetic, tartaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic and similarly known acceptable acids.
The polyethylene glycol component may be comprised of one or more PEG polymers, preferably commercially available PEG polymers between PEG 200 and
PEG 4,000, i.e. those PEG polymers having an average molecular weight between about 190 and about 4800. More preferred are PEG polymers between average molecular weights of from about 190 to about 3450, most preferably between about 400 and 1540. Among the preferred PEG polymers are PEG 400, having an average molecular weight between about 380 and about 420, and PEG 1,000, having an average molecular weight between about 950 and about 1050. The ratio of high and low molecular weight PEG species within the PEG component is preferably from about 2.5:1 to about 1:2.5, more preferably about 1:1. As an example, a preferred blend of PEG polymers within this invention would include a 1 : 1 blend of PEG 400 and PEG 1000. It may be preferable to choose a mixture of PEG components which will have a melting point at or near the physiological temperature of the mammal to receive the formulation. Mixtures of final components which have a viscosity range of from about 140 to about 1500 centipoise at 37°C may be preferred, more preferably a range of from 300 to about 800 centipoise at 37°C.
The surfactants that may be used with the present formulations include, but not limited to, polysorbate 20 (polyoxyethylene 20 sorbitan monolaurate), Polysorbate 60, Polysorbate 40, polysorbate 80, Span 80 Sorbitan Oleate, a product of ICI Americas, Wilmington, Delaware, polysorbate 81, polysorbate 85, polysorbate 120, bile acids and their salts defined by Martindale The Extra Pharmacopoeia Thirtieth Edition on pagel341-1342 such as Sodium taurocholates, Sodium deoxytaurocholates, Chenodeoxycholic acid, and ursodeoxycholic acid, and pluronic or poloxamers such as Pluronic F68, Pluronic L44, Pluronic LlOl, or combinations of one or more of the above. Polysorbate 80, by itself or in combination with one or more other surfactants, is preferred for use with this invention.
The sucrose fatty acid esters useful with this invention include those commercially available and art recognized esters useful for orally administered pharmaceutical compositions, including monoesters, diesters and triesters of sucrose, or mixtures or blends thereof. Specific examples of esters useful with this invention are sucrose monolaurate, sucrose monomyristate, sucrose monopalminate, sucrose monostearate, sucrose distearate, sucrose tristearate, sucrose trimyristate, and sucrose tripalmitate, or combinations thereof. In addition to these components, other enhancing or protective pharmaceutically acceptable antioxidants or preservatives may be added to the compositions of this invention to comprise up to about 4% of the composition, by weight, more preferably up to about 3%. Examples may include ascorbyl palmitate, benzyl alcohol, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc. Examples of these components in the present formulations would include BHA at a concentration from about 0.3% to about 2.5% (% w/w) and BHT at a concentration from about 0.005% to about 0.15% (% w/w), preferably with a mixture of BHA and BHT within these ranges. Further embodiments include about 0.2% BHT.
A formulation of this invention utilizing one or more of these antioxidants or preservatives comprises:
a) from about 1% to about 20% of N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof, preferably from about 1% to about 16% or from about 5% to about 16% or from about 5% to about 18% of this active ingredient;
b) from about 1% to about 18% of a surfactant component, preferably from about 5% to about 18% or from about 5% to about 15% of the surfactant component, more preferably from about 5% to about 10% of the surfactant component;
c) from about 50% to about 80% of a component of one or more different molecular weight grades of polyethylene glycols (PEG), preferably from about 55% to about 70% of one or more polyethylene glycols;
d) from about 1% to about 20%, preferably about 5% to about 15%, of one or more sucrose fatty acid esters or polyvinylpyrrolidone (PVP) with a K value between about 15 and 90, preferably with a K value of from about 17 as defined in USP/NF; and
e) from about 0.1% to about 4%, preferably from about 0.1 to about 3%, of one or more preservatives or antioxidants, for example from about 0.3% to about 2.5% (% w/w) BHA and/or from about 0.005% to about 0.15% (% w/w) BHT.
One preferred embodiment of this invention provides a pharmaceutical formulation comprising:
a) from about 5% to about 16% of N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof;
b) from about 5% to about 10% of a surfactant component;
c) a component of from about 55% to about 70% of one or more different molecular weight grades of polyethylene glycols;
d) from about 5% to about 15% of polyvinylpyrrolidone (PVP) with a K value between about 15 and 90, preferably with a K value of from about 17 as defined in USP/NF; and
e) from about 0.3% to about 2.5% (% w/w) BHA and from about 0.005% to about 0.15% (% w/w) BHT.
Preferably, the formulations of this invention are enclosed in a sealed enclosure after manufacture, such as soft or hard gelatin capsules. The formulations of this invention may be created as a liquid or semi-liquid formulation and introduced into a capsule. Similarly, using an acceptable range of components and/or temperatures, the formulation may be made as a gel or solid prior to encapsulation. Detailed Description of the Invention
This invention also includes a method for producing the formulations disclosed herein. The process comprises the steps of:
a) combining, preferably with mixing or stirring, the PEG and surfactant components to create a first carrier mixture;
b) raising the temperature of the first carrier mixture to a range of from about 75°C to about 95°C, preferably from about 80°C to about 90°C;
c) adding the active pharmacological agent (VPA-985) or a pharmaceutically acceptable salt thereof to create a first pharmaceutical composition mixture;
d) stirring the first pharmaceutical composition mixture, preferably with heating, until the first pharmaceutical composition mixture is clear, preferably at a temperature from about 115°C to about 170°C, preferably from about 130°C to about 170°C, more preferably at a temperature from about 135°C to about 150°C or from about 135°C to about 145°C.
e) cooling the first pharmaceutical composition, if necessary, to a temperature of from about 60°C to about 110°C, preferably from about 80°C to about 90°C;
f) adding the amount of sucrose fatty acid ester(s) and or povidone to create a final pharmaceutical composition mixture, preferably with stirring until the final pharmaceutical composition mixture is clear. In cases wherein optional antioxidants or preservatives are used, such as BHA,
BHT, etc., the following steps may be employed:
a) combining, preferably with mixing or stirring, the PEG component (such as a mixture of PEG 400 and PEG 1000) and the surfactant component (such as Polysorbate 80) to create a first carrier mixture;
b) raising the temperature of the first carrier mixture to a range of from about 75°C to about 95°C, preferably from about 80°C to about 90°C;
c) adding to the first carrier mixture optional antioxidant or preservative components to create a second carrier mixture, which is then stirred or otherwise mixed until the second carrier mixture is a clear solution;
d) adding the active pharmacological agent or drug component (VPA- 985) or a pharmaceutically acceptable salt thereof to create a first pharmaceutical composition mixture;
e) stirring the first pharmaceutical composition mixture, preferably with heating, until the first pharmaceutical composition mixture is clear, preferably at a temperature from about 130°C to about 150°C, more preferably at a temperature from about 135°C to about 145°C;
f) optionally cooling the first pharmaceutical composition to a temperature of from about 75°C to about 95°C, preferably from about 80°C to about 90°C;
& l) adding the amount of sucrose fatty acid ester(s) and/or povidone to create a final pharmaceutical composition mixture, preferably with stirring until the final pharmaceutical composition mixture is clear. One skilled in the art will understand the viscosity and form of the final formulation may be manipulated with components within the scope of this invention and temperature ranges during processing. For instance, a fluid or semi-solid composition may be produced with the more fluid PEG, surfactant and PVP species within the scope of this invention. More gel-like, viscous or semi-solid compositions may be produced with combinations of higher molecular weight PEG components and PVP components having higher K values. Moreover, the components may be cooled below their melting point if milling or other processing of the final composition is desired. To create a more pelletized initial composition, a fluid composition of this invention may be sprayed onto a cooled Teflon®-coated surface to form small solid spheres, which may be individually coated or collected for further processing.
Specific non-limiting examples of formulations within the scope of this invention are provided below.
Example 1
50 mg/capsule: VPA-985 Oral Formulation at 10 % Drug Loading
In place of the polysorbate 80 in this formulation of Example 1, other polysorbate series such as Tween 20, 40 and 60 can also be used, alone or in combination with each other and/or polysorbate 80.
% w/w) per capsule 20,000 (mg) capsule batch (g)
Active Ingredient:
VPA-985 @ 100 % 10.42 50.00 1000.00
Inactive Ingredients:
PEG 1000, NF 30.96 148.61 2,972.16
Povidone USP K-17 10.00 48.00 960.00
Polysorbate 80, NF 10.00 48.00 960.00
BHT, NF 0.09 0.42 8.32
BHA, NF 0.87 4.16 83.2
PEG 400, NF2 Q.S. to Q.S. to Q.S. to 9,600
100 480.00
1. Weigh the Polysorbate 80, PEG 400, and PEG 1000 into a suitable mixing vessel, stir using a top mounted mixer, and warm to 85 ± 5 °C.
2. Add BHT and BHA to the mixing vessel, very slowly to prevent formation of lumps. Continue stirring at 85 ± 5 °C, until a clear solution was formed.
3. Add VPA-985 to the vessel at 85 ± 5 °C , very slowly to prevent formation of lumps. Slowly raise the temperature to 125 ± 5 °C, and stir until VPA- 985 dissolves completely.
4. Cool the solution in step 4. to 60 ± 5 °C. 5. Add Povidone, USP, K-17 (Plasdone C-15, ISP) slowly to step 5, to prevent the formation of lumps.
Let the solution warm up to 85 ± 5 °C. Stir until the solution becomes clear.
6. Encapsulate 480 mg of the finished solution (in step 10) into size 1 capsules at 38 ± 5 °C using either soft or hard gelatin capsule filler. During encapsulation cool the body of capsule using cool Nitrogen to prevent leaking.
7. Band seal the capsules with gelatin solution (optional).
Example 2
50 mg/capsule: VPA-985 Oral Formulation at 10 % Drug Loading
In place of surfactant used in this formulation (poloxamer 188), other polymers in the series such as Pluronic L44, Pluronic LlOl can also be used.
(% w/w) per capsule 20,000
(mg) capsule batch
(g) Active Ingredient:
VPA-985 @ 100 % 10.42 50.00 1000.00
Inactive Ingredients:
Povidone USP K-17 10.00 48.00 960.00
(Plasdone C-15, ISP)
Poloxamer 188, NF 12.00 57.60 1152.00
BHT NF 0.09 0.42 8.32
BHA NF 0.87 4.16 83.20
PEG 400 NF Q. S. to 100 Q.S. to 480.00 Q.S. to 9600 g
This formulation is manufactured the same as that of the formula of Example 1 (50 mg/capsule) with the exception that 12 % of poloxamer was used in place of the polysorbate 80 in this formulation. The encapsulation weight is 480 mg. Example 3 50 mg/capsule
Example 3 provides a formulation with a combination of two or more surfactants.
% w/w) per capsule (mg) 20,000 capsule batch (g)
Active Ingredient:
VPA-985 @ 100 % 10.64 51.07 1,021.44
Inactive Ingredient:
PEG 1000, NF 28.60 137.28 2,745.60
Povidone USP K-17 10.00 48.00 960.00
(Plasdone C-15, ISP)
Polysorbate 40, NF 5.00 24.00 480.00
Poloxamer 188, NF 10.00 48.00
BHT, NF 0.09 0.43 8.64
BHA, NF 0.87 4.18 83.52
PEG 400, NF Q.S. to 100 Q.S. to 480.00 Q.S. to 9600.00
The formulation of Example 3 is manufactured the same as that of Example 1 (50 mg/capsule) with the exception that two surfactants, polysorbate 40 and poloxamer 188 were added in step 1 along with PEG 400 and PEG 1000. The encapsulation weight is 480 mg. Example 4
25 mg/capsule: VPA-985 Oral Formulation at 5 % Drug Loading
(% w/w) per capsule 20,000
(mg) capsule batch (g)
Active Ingredient:
VPA-985 @ 100 % 5.49 25.00 500.00
Inactive Ingredient:
PEG 1000, NF 32.66 148.61 2,972.16
Povidone, USP K-17 10.55 48.00 960.00
(Plasdone C-15, ISP)
Polysorbate 80, NF 10.55 48.00 960.00
BHT, NF 0.09 0.42 8.32
BHA, NF 0.91 4.16 83.2
PEG 400, NF2 Q.S. to 100 Q.S. to Q.S. to
455.00 9,100 g
The formulation of Example 4 is produced in the same manner as that of 50 mg/capsule, above, with the exception that the heating temperature to solubilize VPA- 985 in step 3 is 115 ± 5 °C, instead of 120 ± 5 °C. The encapsulation weight is 455 mg.
Example 5
100 mg/capsule: VPA-985 Oral Formulation at 15 % Drug Loading
Ψc w/w) per capsule 20,000 capsule (mg) batch (g)
Active Ingredient:
VPA-985 @ 100 % 15.38 100.00 2,000.00
Inactive Ingredient:
PEG 1000, NF 28.98 188.35 3,767.05
Povidone USP K-17 10.00 65.00 1,300.00
(Plasdone C-15, ISP)3
Polysorbate 80, NF 9.45 61.39 1,227.91
BHT, NF 0.08 0.53 10.64
BHA, NF 0.82 5.32 106.42
PEG 400, NF Q.S. to 100 Q.S. to 650.00 Q.S. to 13,000.00
This formulation is produced with the same steps as the 50 mg/capsule, above, with the exception that the heating temperature to solubilize VPA-985 in step 3 is 145 ± 5 °C, instead of 120 ± 5 °C. The encapsulation weight is 650 mg in size 0 hard gelatin capsule.
Example 6
VPA-985: 150 mg in Size 00 Capsule
(% w/w) per capsule 20,000 (mg) capsule batch
(g)
Active Ingredient:
VPA-985 @ 100 % 16.48 149.97 2,999.36
Inactive Ingredients: PEG 1000, NF 26.3 239.33 4,786.60 Povidone USP K-17 15 136.50 2,730.00
(Plasdone C-15, ISP) Polysorbate 80, NF 9.32 84.81 1,696.24 BHT, NF 0.08 0.73 14.56 BHA, NF 0.81 7.37 147.42 PEG 400, NF Q.S. to 100 Q.S. to Q.S. to
910.00 18,200.00
This formulation of Example 6 is produced with the same steps as that of 50 mg/capsule with the exception of the heating temperature to solubilize VPA-985 in step 3 is 150 ± 5 °C, instead of 145 ± 5 °C. The encapsulation weight is 910 mg in size 00 hard gelatin capsule.
The following specific Examples 7 through 11 shown in Table 1, below, were formulated as described above to create formulations of 10% N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methyl- benzamide (VPA-985) with varying concentrations of PEG 400, PEG 1000, two PVP components with respective K values of 15 and 90, and a combination of BHA and BHT as an adjuvant component. Table 1
Example PEG PEG PVP P PVVPP BHT BHA NATC VPA-
No. 400 1000 K15 K90 985
(%) (%) (%) (%) (%) (%) (%) (%)
7 55.40 20.00 10.00 0.00 0.20 2.00 2.40 10.00
8 40.40 35.00 10.00 0.00 0.20 2.00 2.40 10.00
9 75.40 0.00 5.00 5.00 0.20 2.00 2.40 10.00
10 65.40 10.00 0.00 1 100..00C0 0.20 2.00 2.40 10.00
11 40.40 35.00 5.00 5.00 0.20 2.00 2.40 10.00
Similarly, the following Examples 12 through 32 were formulated by the methods herein using PEG 400, PEG 1000, PVP with a K value of 17, VPA-985, BHA and BHT as antioxidants or preservatives and the additional components listed as "other".
Table 2 Ex. PEG PEG PVP VPA- BHA BHT Other Other
No. 400 1000 K-17 985
12 40.40 35.00 10.00 10.00 2.00 0~20 Sodium
Taurocholate 2.40
13 75.40 - 5.00 10.21 2.00 0.20 Sodium PVP
Taurocholate K-90
2.40 5.00
14 42.59 35.00 10.00 10.21 2.00 0.20
15 34.35 28.23 10.00 10.21 2.00 0.20 Poloxamer 188
15.00
16 42.59 20.00 10.00 10.21 2.00 0.20 Poloxamer 188
15.00 37.10 30.49 10.00 10.21 2.00 0.20 Poloxamer 188
10.00 35.72 29.36 10.00 10.21 2.00 0.20 Poloxamer 188
12.50 34.35 28.23 10.00 10.21 2.00 0.20 Poloxamer 188
15.00 37.10 30.49 10.00 10.21 2.00 0.20 Poloxamer 188
10.00 34.35 28.23 10.00 10.21 2.00 0.20 Poloxamer 188
15.00 35.72 29.36 10.00 10.21 2.00 0.20 Poloxamer 188
12.50 36.86 30.30 10.00 10.64 2.00 0.20 Pluronic L44
10.00 36.86 30.30 10.00 10.64 2.00 0.20 Pluronic LlOl
10.00 39.61 32.55 10.00 10.64 2.00 0.20 Tween 40
5.00 41.25 33.91 10.00 10.64 2.00 0.20 Tween 40
2.00 39.61 32.55 10.00 10.64 2.00 0.20 Tween 20
5.00 41.25 33.91 10.00 10.64 2.00 0.20 Tween 20
2.00 34.12 28.04 10.00 10.64 2.00 0.20 Tween 40 Poloxamer 188
5.00 10.00 30 36.86 30.30 10.00 10.64 2.00 0.20 Tween 40 -
10.00
31 36.86 30.30 10.00 10.64 2.00 0.20 Tween 80 -
10.00
32 34.12 28.04 10.00 10.64 2.00 0.20 Tween 80 Poloxamer 188
5.00 10.00
Example 33
25 mg/capsule in Size #3 capsule: Oral formulation at 10 % Drug Loading In place of the polysorbate 80, other polysorbate series such as Tween 20, 40 and 60 can also be used.
(% w/w) per capsule 20,000 (mg) capsule batch
(g)
Active Ingredient: VPA-985 @100% 10.42 25 500.00
Inactive Ingredients:
PEG 1000, NF 30.96 74.31 1,486.08
Povidone USP K-17 10.00 24.00 480.00
Polysorbate 80, NF 10.00 24.00 480.00
BHT, NF 0.09 0.21 4.16
BHA, NF 0.87 2.08 41.6
PEG 400, NF2 Q.S. to 100 Q.S. to 240 Q.S. to 4800

Claims

1. A pharmaceutical composition comprising (by % weight/weight): a) from about 1 % to about 20% of N-[4-(5H-pyrrolo[2, 1- c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof;
b) from about 1% to about 18% of a surfactant component;
c) from about 50% to about 80% of a component of one or more polyethylene glycols; and
d) from about 1% to about 20% of a component of: i) one or more sucrose fatty acid esters; or ii) a polyvinylpyrrolidone with a K value between about 15 and 90; or iii) a combination of one or more sucrose fatty acid esters and polyvinylpyrrolidone.
2. A pharmaceutical composition of Claim 1 comprising (by % weight/weight):
a) from about 5% to about 16% of N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5~fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof;
b) from about 5% to about 18% of a surfactant component;
c) from about 55% to about 70% of a component of one or more polyethylene glycols; and d) from about 1% to about 20% of a component of: i) one or more sucrose fatty acid esters; or ii) a polyvinylpyrrolidone with a K value between about 15 and
90; or iii) a combination of one or more sucrose fatty acid esters and polyvinylpyrrolidone, as defined above.
3. A pharmaceutical composition of Claim 1 wherein the surfactant component comprises polysorbate 20, polysorbate 60, polysorbate 40, polysorbate 80, Span 80 Sorbitan Oleate, polysorbate 81, polysorbate 85, polysorbate 120, sodium taurocholates, sodium deoxytaurocholates, chenodeoxycholic acid, ursodeoxycholic acid, pluronic or poloxamers, or combinations thereof.
4. A pharmaceutical composition of Claim 1 wherein the component of one or more polyethylene glycols comprises one or more polyethylene glycols having an average molecular weight between about 190 to about 3450.
5. A pharmaceutical composition of Claim 4 wherein the component of one or more polyethylene glycols comprises one or more polyethylene glycols having an average molecular weight between about 400 and 1540.
6. A pharmaceutical composition of Claim 4 wherein the component of one or more polyethylene glycols comprises a mixture of PEG 400 and PEG 1000 in a ratio of between about 2.5:1 to about 1:2.5.
7. A pharmaceutical composition of Claim 1 wherein the polyvinylpyrrolidone component has a K value of about 17.
8. A pharmaceutical composition comprising (by % weight/weight): a) from about 1% to about 20% of N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(l lH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof;
b) from about 5% to about 18% of a surfactant component;
c) from about 50% to about 80% of a component of one or more polyethylene glycols;
d) from about 1 % to about 20% of one or more sucrose fatty acid esters or polyvinylpyrrolidone with a K value between about 15 and 90; and
e) from about 0.1% to about 3% of one or more antioxidants or preservatives.
9. A pharmaceutical composition of Claim 8 wherein: a) the surfactant component comprises polysorbate 20, polysorbate 60, polysorbate 40, polysorbate 80, Span 80 Sorbitan Oleate, polysorbate 81, polysorbate 85, polysorbate 120, sodium taurocholates, sodium deoxytaurocholates, chenodeoxycholic acid, ursodeoxycholic acid, pluronic or poloxamers, or combinations thereof; b) the component of one or more polyethylene glycols comprises one or more polyethylene glycols having an average molecular weight between about 400 and 1540; and c) the one or more antioxidants or preservatives are selected from ascorbyl palmitate, benzyl alcohol, butylated hydroxyanisole, or butylated hydroxytoluene, or combinations thereof.
10. A pharmaceutical composition of Claim 8 comprising (by % weight/weight): a) from about 5% to about 16% of N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof;
b) from about 5% to about 18% of a surfactant component;
c) from about 55% to about 70% of a component of one or more polyethylene glycols;
d) from about 1% to about 20% of one or more sucrose fatty acid esters or polyvinylpyrrolidone with a K value between about 15 and 90;
e) from about 0.3% to about 2.5% (% weight/weight) BHA and/or from about 0.005% to about 0.15% (% weight/weight) BHT.
11. A pharmaceutical composition of Claim 8 comprising (by % weight/weight):
a) from about 5% to about 16% of N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof;
b) from about 5% to about 18% of a surfactant component comprising polysorbate 20, polysorbate 60, polysorbate 40, polysorbate 80, Span 80 Sorbitan Oleate, polysorbate 81, polysorbate 85, polysorbate 120, sodium taurocholates, sodium deoxytaurocholates, chenodeoxycholic acid, ursodeoxycholic acid, pluronic or poloxamers, or combinations thereof;
c) a component of from about 55% to about 70% of one or more polyethylene glycols having an average molecular weight between about 400 and 1540; d) from about 1% to about 20% of polyvinylpyrrolidone (PVP) with a K value between about 15 and 90; and
e) from about 0.3% to about 2.5% (% weight/weight) BHA and from about 0.005% to about 0.15% (% weight/weight) BHT.
12. A pharmaceutical composition of Claim 1 which is contained within a hard or soft gelatin capsule.
13. A process for formulating a pharmaceutical composition which comprises (by % weigth/weight) from about 1% to about 20% of N-[4-(5H- pyrrolo[2,l-c][l,4]benzodiazepin-10(llH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof; from about 1% to about 18% of a surfactant component; from about 50% to about 80% of a component of one or more polyethylene glycols; and from about 1% to about 20% of a component of one or more sucrose fatty acid esters or a polyvinylpyrrolidone with a K value between about 15 and 90; or a combination of one or more sucrose fatty acid esters and polyvinylpyrrolidone; the process comprising the steps of:
a) combining the surfactant component and the component of one or more polyethylene glycols to create a first carrier mixture;
b) raising the temperature of the first carrier mixture to a range of from about 75°C to about 95°C;
c) adding the N-[4-(5H-pyrrolo[2,l-c][l,4]benzodiazepin-10(l lH)yl- carbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide, or a pharmaceutically acceptable salt thereof, to create a first pharmaceutical composition mixture; d) stirring the first pharmaceutical composition until the first pharmaceutical composition mixture is clear;
e) cooling the first pharmaceutical composition, if necessary, to a temperature of from about 75°C to about 95°C;
f) adding the amount of one or more sucrose fatty acid esters and/or povidone to create a final pharmaceutical composition mixture.
14. A process of Claim 13 comprising the steps:
a) combining the surfactant component and the component of one or more polyethylene glycols to create a first carrier mixture;
b) raising the temperature of the first carrier mixture to a range of from 80°C to about 90°C;
c) adding the N-[4-(5H-pyrrolo[2,l-c][l,4]benzodiazepin-10(llH)yl- carbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide, or a pharmaceutically acceptable salt thereof, to create a first pharmaceutical composition mixture;
d) stirring the first pharmaceutical composition until the first pharmaceutical composition mixture is clear;
e) cooling the first pharmaceutical composition, if necessary, to a temperature of from about 80°C to about 90°C;
f) adding the amount of sucrose fatty acid ester(s) and/or povidone to create a final pharmaceutical composition mixture.
15. A process for formulating a pharmaceutical composition comprising (by % weight/weight) from about 1% to about 20% of N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(llH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof; from about 5% to about 18% of a surfactant component; from about 50% to about 80% of a component of one or more polyethylene glycols; a component of from about 1% to about 20% of one or more sucrose fatty acid esters or polyvinylpyrrolidone with a K value between about 15 and 90; and from about 0.1% to about 3% of one or more adjuvants; the process comprising the steps of:
a) combining the component of one or more polyethylene glycols and the surfactant component to create a first carrier mixture;
b) raising the temperature of the first carrier mixture to a range of from about 75°C to about 95°C;
c) adding to the first carrier mixture the one or more antioxidants or preservatives to create a second carrier mixture;
d) adding the N-[4-(5H-pyrrolo[2,l-c][l,4]benzodiazepin-10(l lH)yl- carbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide, or a pharmaceutically acceptable salt thereof, to create a first pharmaceutical composition mixture;
e) stirring the first pharmaceutical composition mixture;
f) optionally cooling the first pharmaceutical composition to a temperature of from about 75°C to about 95°C; g) adding the component of from about 1% to about 20% of one or more sucrose fatty acid esters or polyvinylpyrrolidone with a K value between about 15 and 90 to create a final pharmaceutical composition mixture.
16. The process of Claim 15 wherein: a) the surfactant component comprises polysorbate 20, polysorbate 60, polysorbate 40, polysorbate 80, Span 80 Sorbitan Oleate, polysorbate 81, polysorbate 85, polysorbate 120, sodium taurocholates, sodium deoxytaurocholates, chenodeoxycholic acid, ursodeoxycholic acid, pluronic or poloxamers, or combinations thereof; b) the component of one or more polyethylene glycols comprises one or more polyethylene glycols having an average molecular weight between about 400 and 1540; and c) the one or more antioxidants or preservatives are selected from ascorbic palmitate, benzyl alcohol, butylated hydroxyanisole, or butylated hydroxytoluene, or combinations thereof.
17. A process for formulating a pharmaceutical composition comprising (by % weight/weight) from about 1% to about 20% of N-[4-(5H-pyrrolo[2,l- c] [ 1 ,4]benzodiazepin- 10( 1 lH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof; from about 5% to about 18% of a surfactant component; from about 50% to about 80% of a component of one or more polyethylene glycols; a component of from about 1% to about 20% of polyvinylpyrrolidone with a K value between about 15 and 90; and an antioxidant or preservative component of from about 0.3% to about 2.5% butylated hydroxyanisole and from about 0.005% to about 0.15% butylated hydroxytoluene; the process comprising the steps of:
a) combining, preferably with mixing or stirring, the component of one or more polyethylene glycols and the surfactant component to create a first carrier mixture; b) raising the temperature of the first carrier mixture to a range of from about 75°C to about 95°C;
c) adding to the first carrier mixture the antioxidant or preservative component to create a second carrier mixture;
d) adding the N-[4-(5H-pyrrolo[2,l-c][l,4]benzodiazepin-10(l lH)yl- carbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide, or a pharmaceutically acceptable salt thereof to create a first pharmaceutical composition mixture;
e) stirring or mixing the first pharmaceutical composition mixture until the first pharmaceutical composition mixture is clear;
f) bringing the first pharmaceutical composition to a temperature of from about 75°C to about 95°C;
g) adding the component of from about 1% to about 20% of povidone to create a final pharmaceutical composition mixture.
18. The process of Claim 17 wherein: a) the surfactant component comprises polysorbate 20, polysorbate 60, polysorbate 40, polysorbate 80, Span 80 Sorbitan Oleate, polysorbate 81, polysorbate 85, polysorbate 120, sodium taurocholates, sodium deoxytaurocholates, chenodeoxycholic acid, ursodeoxycholic acid, pluronic or poloxamers, or combinations thereof; and b) the component of one or more polyethylene glycols comprises one or more polyethylene glycols having an average molecular weight between about 400 and 1540.
19. A process for formulating a pharmaceutical composition comprising (by % weight/weight) from about 5% to about 16% of N-[4-(5H-pyrrolo[2,l- c][l,4]benzodiazepin-10(HH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2- methylbenzamide, or a pharmaceutically acceptable salt thereof; from about 5% to about 18% of a surfactant component; from about 55% to about 70% of a component of one or more polyethylene glycols; a component of from about 5% to about 15% of polyvinylpyrrolidone with a K value between about 15 and 90; and an antioxidant or preservative component of from about 0.3% to about 2.5% butylated hydroxyanisole and from about 0.005% to about 0.15% butylated hydroxytoluene; the process comprising the steps of:
a) combining, preferably with mixing or stirring, the component of one or more polyethylene glycols and the surfactant component to create a first carrier mixture;
b) raising the temperature of the first carrier mixture to a range of from about 80°C to about 90°C;
c) adding to the first carrier mixture the antioxidant or preservative component to create a second carrier mixture;
d) adding the N-[4-(5H-pyrrolo[2,l-c][l,4]benzodiazepin- 10(1 lH)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide, or a pharmaceutically acceptable salt thereof to create a first pharmaceutical composition mixture;
e) raising the temperature of the first pharmaceutical composition mixture to a temperature from about 135°C to about 145°C;
f) stirring or mixing the first pharmaceutical composition mixture until the first pharmaceutical composition mixture is clear; g) bringing the first pharmaceutical composition to a temperature of from about 80°C to about 90°C;
h) adding the component of from about 5% to about 15% of povidone to create a final pharmaceutical composition mixture.
PCT/US2000/026369 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process WO2001022945A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU76150/00A AU7615000A (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process
EP00965430A EP1216033A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process
PL00354282A PL354282A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process
HU0202972A HUP0202972A3 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process for its preparation
IL14854100A IL148541A0 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process
MXPA02003189A MXPA02003189A (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process.
JP2001526157A JP2003510269A (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulations and methods
EA200200414A EA200200414A1 (en) 1999-09-27 2000-09-26 COMPOSITION OF ANTAGONIST VAZOPRESSIN AND METHOD FOR ITS OBTAINING
BR0014351-0A BR0014351A (en) 1999-09-27 2000-09-26 Formulation and process of vasopressin antagonist
KR1020027003931A KR20020039354A (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process
CA002388474A CA2388474A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process
NO20021475A NO20021475L (en) 1999-09-27 2002-03-25 Vasopressin antagonist, formulation and method
HK02106544.6A HK1045109A1 (en) 1999-09-27 2002-09-05 Vasopressin antagonist formulation and process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40577299A 1999-09-27 1999-09-27
US09/405,772 1999-09-27

Publications (1)

Publication Number Publication Date
WO2001022945A1 true WO2001022945A1 (en) 2001-04-05

Family

ID=23605168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026369 WO2001022945A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process

Country Status (18)

Country Link
EP (1) EP1216033A1 (en)
JP (1) JP2003510269A (en)
KR (1) KR20020039354A (en)
CN (1) CN1391466A (en)
AR (1) AR025780A1 (en)
AU (1) AU7615000A (en)
BR (1) BR0014351A (en)
CA (1) CA2388474A1 (en)
CZ (1) CZ20021083A3 (en)
EA (1) EA200200414A1 (en)
HK (1) HK1045109A1 (en)
HU (1) HUP0202972A3 (en)
IL (1) IL148541A0 (en)
MX (1) MXPA02003189A (en)
NO (1) NO20021475L (en)
PL (1) PL354282A1 (en)
WO (1) WO2001022945A1 (en)
ZA (1) ZA200203312B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003072085A1 (en) * 2002-02-27 2005-06-16 塩野義製薬株式会社 Solid formulation with improved absorption of poorly water-soluble drugs
CN1292746C (en) * 2001-04-17 2007-01-03 法马西亚公司 Amino-sulfonyl-containing active compound (COX-2 inhibitors), polyethylene glycol and removing free radical antioxidate and liquid

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5873375B2 (en) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 Soft capsule and method for producing soft capsule

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
WO1999036060A1 (en) * 1998-01-20 1999-07-22 Applied Analytical Industries, Inc. Oral liquid compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
WO1999036060A1 (en) * 1998-01-20 1999-07-22 Applied Analytical Industries, Inc. Oral liquid compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1292746C (en) * 2001-04-17 2007-01-03 法马西亚公司 Amino-sulfonyl-containing active compound (COX-2 inhibitors), polyethylene glycol and removing free radical antioxidate and liquid
JPWO2003072085A1 (en) * 2002-02-27 2005-06-16 塩野義製薬株式会社 Solid formulation with improved absorption of poorly water-soluble drugs
JP4632288B2 (en) * 2002-02-27 2011-02-16 塩野義製薬株式会社 Solid formulation with improved absorption of poorly water-soluble drugs

Also Published As

Publication number Publication date
CZ20021083A3 (en) 2002-06-12
KR20020039354A (en) 2002-05-25
CN1391466A (en) 2003-01-15
NO20021475D0 (en) 2002-03-25
AR025780A1 (en) 2002-12-11
AU7615000A (en) 2001-04-30
IL148541A0 (en) 2002-09-12
HUP0202972A3 (en) 2003-07-28
EA200200414A1 (en) 2002-12-26
CA2388474A1 (en) 2001-04-05
NO20021475L (en) 2002-04-16
HK1045109A1 (en) 2002-11-15
MXPA02003189A (en) 2002-09-30
JP2003510269A (en) 2003-03-18
BR0014351A (en) 2002-06-11
PL354282A1 (en) 2003-12-29
HUP0202972A2 (en) 2002-12-28
ZA200203312B (en) 2003-12-31
EP1216033A1 (en) 2002-06-26

Similar Documents

Publication Publication Date Title
US6437006B1 (en) Pharmaceutical carrier formulation
EP1185273B1 (en) Antifungal oral composition containing itraconazole and process for preparing same
EP2451438B1 (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
US6221391B1 (en) Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
HU225535B1 (en) Microemulsion pre-concentrate and microemulsion
NL193267C (en) Pharmaceutical preparation in the form of a gelatin capsule with a filling containing ranitidine hydrochloride.
SK17222001A3 (en) Substantially oil-free cyclosporin compositions
US6352718B1 (en) Vasopressin antagonist formulation and process
JP5750278B2 (en) Candesartan cilexetil capsule filling composition
EP1216033A1 (en) Vasopressin antagonist formulation and process
EP1216029A1 (en) Pharmaceutical carrier formulation
EP3854384A1 (en) Pharmaceutical formulation comprising abiraterone acetate
KR20080038133A (en) Controlled release of hypnotic agents
WO2004062692A1 (en) Formulation of poorly water-soluble active substances
EP0326103B1 (en) Pharmaceutical composition for 4-aroylimidazol-2-ones
EP3510997B1 (en) Soft gelatin capsules comprising a suspension of tadalafil
US6979672B2 (en) Cyclosporin-based pharmaceutical compositions
US20040082600A1 (en) Pharmaceutical composition
JPH04356420A (en) Thiamine-cobalt-chlorophyllin complex compound-containing composition
WO2014010008A1 (en) Capsule-filling composition of candesartan cilexetil
WO2001023366A2 (en) Vasopressin antagonist and diuretic combination
MXPA06005247A (en) Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative
CZ20001876A3 (en) Preparations containing dissolved paroxetine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 148541

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000965430

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2001 526157

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 517984

Country of ref document: NZ

Ref document number: 76150/00

Country of ref document: AU

Ref document number: 2388474

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003189

Country of ref document: MX

Ref document number: 1020027003931

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2002-1083

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 200200414

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 008160082

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027003931

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-1083

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000965430

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: PV2002-1083

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000965430

Country of ref document: EP